Key result
Phosphorylated S15D-D166V myosin RLC restores maximal contractile tension ~15 kN/m2 and prevents HCM-related hypertrophy.
Constitutive phosphorylation of cardiac myosin regulatory light chain prevents the development of the pathological hypertrophic cardiomyopathy phenotype in a mouse model.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for RLC phosphorylation in HCM; requires human validation before clinical consideration.
Myosin light chain kinase (MLCK)-dependent phosphorylation of the regulatory light chain (RLC) of cardiac myosin is known to play a beneficial role in heart disease, but the idea of a phosphorylation-mediated reversal of a hypertrophic cardiomyopathy (HCM) phenotype is novel. Our previous studies on transgenic (Tg) HCM-RLC mice revealed that the D166V (Aspartate166 → Valine) mutation-induced changes in heart morphology and function coincided with largely reduced RLC phosphorylation in situ. We hypothesized that the introduction of a constitutively phosphorylated Serine15 (S15D) into the hearts of D166V mice would prevent the development of a deleterious HCM phenotype. In support of this notion, MLCK-induced phosphorylation of D166V-mutated hearts was found to rescue some of their abnormal contractile properties. Tg-S15D-D166V mice were generated with the human cardiac RLC-S15D-D166V construct substituted for mouse cardiac RLC and were subjected to functional, structural, and morphological assessments. The results were compared with Tg-WT and Tg-D166V mice expressing the human ventricular RLC-WT or its D166V mutant, respectively. Echocardiography and invasive hemodynamic studies demonstrated significant improvements of intact heart function in S15D-D166V mice compared with D166V, with the systolic and diastolic indices reaching those monitored in WT mice. A largely reduced maximal tension and abnormally high myofilament Ca(2+) sensitivity observed in D166V-mutated hearts were reversed in S15D-D166V mice. Low-angle X-ray diffraction study revealed that altered myofilament structures present in HCM-D166V mice were mitigated in S15D-D166V rescue mice. Our collective results suggest that expression of pseudophosphorylated RLC in the hearts of HCM mice is sufficient to prevent the development of the pathological HCM phenotype.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2015) studied Hypertrophic cardiomyopathy (HCM) (n=208). Constitutive pseudophosphorylation of cardiac myosin regulatory light chain at Serine15 (Tg-S15D-D166V) vs. Transgenic D166V HCM mutant mice (Tg-D166V) and Wild-Type mice (Tg-WT) was evaluated on Maximal contractile tension in skinned papillary muscle strips (kN/m2) (MD 15.0 kN/m2, p=<0.001). Constitutively phosphorylated S15D-D166V myosin RLC rescued maximal contractile tension to 41.9 kN/m2 compared to 26.9 kN/m2 in D166V HCM mice and prevented cardiac hypertrophy.
Synapse has enriched 10 related papers. Consider them for comparative context: